SG11201901633WA - 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection - Google Patents
7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infectionInfo
- Publication number
- SG11201901633WA SG11201901633WA SG11201901633WA SG11201901633WA SG11201901633WA SG 11201901633W A SG11201901633W A SG 11201901633WA SG 11201901633W A SG11201901633W A SG 11201901633WA SG 11201901633W A SG11201901633W A SG 11201901633WA SG 11201901633W A SG11201901633W A SG 11201901633WA
- Authority
- SG
- Singapore
- Prior art keywords
- shanghai
- building
- international
- road
- pct
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title abstract 3
- 230000009385 viral infection Effects 0.000 title abstract 3
- -1 7-substituted sulfonimidoylpurinone compounds Chemical class 0.000 title abstract 2
- 238000011321 prophylaxis Methods 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 244000061408 Eugenia caryophyllata Species 0.000 abstract 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2016097140 | 2016-08-29 | ||
| CN2017092653 | 2017-07-12 | ||
| PCT/EP2017/071514 WO2018041763A1 (en) | 2016-08-29 | 2017-08-28 | 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901633WA true SG11201901633WA (en) | 2019-03-28 |
Family
ID=59738346
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901633WA SG11201901633WA (en) | 2016-08-29 | 2017-08-28 | 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection |
| SG10202010520SA SG10202010520SA (en) | 2016-08-29 | 2017-08-28 | 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202010520SA SG10202010520SA (en) | 2016-08-29 | 2017-08-28 | 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US10233184B2 (sr) |
| EP (2) | EP3865482A1 (sr) |
| JP (2) | JP7013467B2 (sr) |
| KR (2) | KR102459155B1 (sr) |
| CN (1) | CN109641904B (sr) |
| AU (3) | AU2017320742B2 (sr) |
| CA (1) | CA3034148A1 (sr) |
| CL (1) | CL2019000512A1 (sr) |
| CO (1) | CO2019000932A2 (sr) |
| CR (1) | CR20190087A (sr) |
| DK (1) | DK3504210T3 (sr) |
| ES (1) | ES2867849T3 (sr) |
| HR (1) | HRP20210621T1 (sr) |
| HU (1) | HUE053944T2 (sr) |
| IL (3) | IL293475B2 (sr) |
| MA (1) | MA46038B1 (sr) |
| MX (2) | MX383500B (sr) |
| MY (1) | MY197408A (sr) |
| PE (1) | PE20190476A1 (sr) |
| PH (1) | PH12019500432B1 (sr) |
| PL (1) | PL3504210T3 (sr) |
| PT (1) | PT3504210T (sr) |
| RS (1) | RS61752B1 (sr) |
| RU (1) | RU2751349C2 (sr) |
| SG (2) | SG11201901633WA (sr) |
| SI (1) | SI3504210T1 (sr) |
| TW (1) | TWI671300B (sr) |
| UA (1) | UA124270C2 (sr) |
| WO (1) | WO2018041763A1 (sr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3294740T3 (pl) * | 2015-05-08 | 2020-03-31 | F. Hoffmann-La Roche Ag | Nowe sulfonoimidoilopurynony i pochodne do leczenia i profilaktyki infekcji wirusowych |
| PL3504210T3 (pl) * | 2016-08-29 | 2021-07-05 | F. Hoffmann-La Roche Ag | 7-podstawione związki sulfonimidoilopurynonowe do leczenia i profilaktyki zakażeń wirusowych |
| EP3512556B1 (en) * | 2016-09-13 | 2021-08-18 | F. Hoffmann-La Roche AG | Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor |
| JP7328977B2 (ja) | 2018-02-12 | 2023-08-17 | エフ． ホフマン－ラ ロシュ アーゲー | ウイルス感染の処置および予防のための新規のスルホン化合物および誘導体 |
| JP7089596B2 (ja) * | 2018-02-28 | 2022-06-22 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 肝がんの治療及び予防のための７位置換スルホンイミドイルプリノン化合物及び誘導体 |
| MX2021002764A (es) | 2018-09-12 | 2021-05-12 | Silverback Therapeutics Inc | Composiciones para el tratamiento de enfermedades con conjugados inmunoestimuladores. |
| WO2020162705A1 (ko) | 2019-02-08 | 2020-08-13 | 성균관대학교산학협력단 | 톨-유사 수용체 7 또는 8 작용자와 콜레스테롤의 결합체 및 그 용도 |
| CA3151322A1 (en) | 2019-10-01 | 2021-04-08 | Silverback Therapeutics, Inc. | Combination therapy with immune stimulatory conjugates |
| JP7735291B2 (ja) | 2020-02-21 | 2025-09-08 | エーアールエス ファーマシューティカルズ、インコーポレイテッド | ネクチン－４抗体コンジュゲートおよびその使用 |
| CA3170551A1 (en) | 2020-03-02 | 2021-09-10 | Yong Taik Lim | Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof |
| JP2023532304A (ja) | 2020-07-01 | 2023-07-27 | エーアールエス ファーマシューティカルズ オペレーションズ，インク． | 抗ａｓｇｒ１抗体コンジュゲートおよびその使用 |
| US20230277525A1 (en) | 2020-08-04 | 2023-09-07 | Progeneer Inc | Conjugate of functional drug and toll-like receptor 7 or 8 agonist of which active site is temporarily inactivated and use thereof |
| JP7690221B2 (ja) | 2020-08-04 | 2025-06-10 | プロジェニア インコーポレイテッド | 動力学的に作用するアジュバントアンサンブル |
| US20230346924A1 (en) | 2020-08-04 | 2023-11-02 | Progeneer Inc. | Mrna vaccine comprising adjuvant capable of kinetic control |
| CN114787165B (zh) * | 2020-09-27 | 2023-02-28 | 上海维申医药有限公司 | 大环tlr7激动剂、其制备方法、药物组合物及其用途 |
| GB202306325D0 (en) | 2023-04-28 | 2023-06-14 | Iksuda Therapeutics Ltd | Antibody-drug conjugate compounds, and methods of use and treatment |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0141927B1 (en) * | 1983-08-18 | 1991-10-30 | Beecham Group Plc | Antiviral guanine derivatives |
| ES2232871T3 (es) | 1996-07-03 | 2005-06-01 | Sumitomo Pharmaceuticals Company, Limited | Nuevos derivados de purina. |
| AUPO912997A0 (en) | 1997-09-11 | 1997-10-02 | Commonwealth Scientific And Industrial Research Organisation | Antiviral agents |
| DE69817393T2 (de) * | 1997-11-28 | 2004-06-17 | Sumitomo Pharmaceuticals Co., Ltd. | Neue heterozyklische verbindungen |
| JPH11180981A (ja) * | 1997-12-19 | 1999-07-06 | Sumitomo Pharmaceut Co Ltd | 複素環誘導体 |
| TW572758B (en) | 1997-12-22 | 2004-01-21 | Sumitomo Pharma | Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives |
| JP4189048B2 (ja) | 1997-12-26 | 2008-12-03 | 大日本住友製薬株式会社 | 複素環化合物 |
| CA2479037C (en) | 2002-03-15 | 2010-11-09 | Jiri Zemlicka | 2-amino-9[(2-hydroxymethyl)cyclopropylidenemethyl]purines as antiviral agents |
| MXPA05003193A (es) * | 2002-09-27 | 2005-06-08 | Sumitomo Pharma | Compuesto de adenina novedoso y uso del mismo. |
| AU2006242920A1 (en) | 2005-05-04 | 2006-11-09 | Pfizer Limited | 2-amido-6-amino-8-oxopurine derivatives as Toll-Like receptor modulators for the treatment of cancer and viral infections, such as hepatitis C |
| DE102006053049A1 (de) | 2006-11-10 | 2008-05-15 | Daimler Ag | Staufach mit einer Abdeckeinrichtung |
| CA2691444C (en) * | 2007-06-29 | 2016-06-14 | Gilead Sciences, Inc. | Purine derivatives and their use as modulators of toll-like receptor 7 |
| CN101239980B (zh) | 2008-02-18 | 2011-06-22 | 靳广毅 | 免疫受体调节剂偶联体前体和偶联体及其应用 |
| RS53347B (sr) * | 2008-12-09 | 2014-10-31 | Gilead Sciences, Inc. | Modulatori toll-sličnih receptora |
| JP5694345B2 (ja) * | 2009-10-22 | 2015-04-01 | ギリアード サイエンシーズ， インコーポレイテッド | Ｔｏｌｌ様受容体の調節因子 |
| US20110150836A1 (en) | 2009-12-22 | 2011-06-23 | Gilead Sciences, Inc. | Methods of treating hbv and hcv infection |
| US8501724B1 (en) * | 2012-01-31 | 2013-08-06 | Pharmacyclics, Inc. | Purinone compounds as kinase inhibitors |
| HRP20210927T1 (hr) | 2014-08-15 | 2021-09-03 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Spojevi pirolopirimidina koje se koriste kao agonist tlr7 |
| PL3294740T3 (pl) * | 2015-05-08 | 2020-03-31 | F. Hoffmann-La Roche Ag | Nowe sulfonoimidoilopurynony i pochodne do leczenia i profilaktyki infekcji wirusowych |
| PL3504210T3 (pl) * | 2016-08-29 | 2021-07-05 | F. Hoffmann-La Roche Ag | 7-podstawione związki sulfonimidoilopurynonowe do leczenia i profilaktyki zakażeń wirusowych |
-
2017
- 2017-08-28 PL PL17758527T patent/PL3504210T3/pl unknown
- 2017-08-28 CA CA3034148A patent/CA3034148A1/en active Pending
- 2017-08-28 WO PCT/EP2017/071514 patent/WO2018041763A1/en not_active Ceased
- 2017-08-28 SG SG11201901633WA patent/SG11201901633WA/en unknown
- 2017-08-28 DK DK17758527.0T patent/DK3504210T3/da active
- 2017-08-28 TW TW106129087A patent/TWI671300B/zh active
- 2017-08-28 PT PT177585270T patent/PT3504210T/pt unknown
- 2017-08-28 EP EP20207475.3A patent/EP3865482A1/en not_active Withdrawn
- 2017-08-28 KR KR1020197008982A patent/KR102459155B1/ko active Active
- 2017-08-28 SI SI201730728T patent/SI3504210T1/sl unknown
- 2017-08-28 UA UAA201903059A patent/UA124270C2/uk unknown
- 2017-08-28 SG SG10202010520SA patent/SG10202010520SA/en unknown
- 2017-08-28 HU HUE17758527A patent/HUE053944T2/hu unknown
- 2017-08-28 EP EP17758527.0A patent/EP3504210B1/en active Active
- 2017-08-28 JP JP2019532184A patent/JP7013467B2/ja active Active
- 2017-08-28 CN CN201780052692.6A patent/CN109641904B/zh active Active
- 2017-08-28 KR KR1020227036198A patent/KR20220147702A/ko not_active Ceased
- 2017-08-28 MA MA46038A patent/MA46038B1/fr unknown
- 2017-08-28 ES ES17758527T patent/ES2867849T3/es active Active
- 2017-08-28 AU AU2017320742A patent/AU2017320742B2/en active Active
- 2017-08-28 PE PE2019000346A patent/PE20190476A1/es unknown
- 2017-08-28 MX MX2019002129A patent/MX383500B/es unknown
- 2017-08-28 HR HRP20210621TT patent/HRP20210621T1/hr unknown
- 2017-08-28 MY MYPI2019001082A patent/MY197408A/en unknown
- 2017-08-28 RU RU2019107957A patent/RU2751349C2/ru active
- 2017-08-28 CR CR20190087A patent/CR20190087A/es unknown
- 2017-08-28 IL IL293475A patent/IL293475B2/en unknown
- 2017-08-28 IL IL284255A patent/IL284255B/en unknown
- 2017-08-28 RS RS20210489A patent/RS61752B1/sr unknown
- 2017-08-28 PH PH1/2019/500432A patent/PH12019500432B1/en unknown
- 2017-08-29 US US15/689,136 patent/US10233184B2/en active Active
-
2019
- 2019-01-29 US US16/260,744 patent/US10752630B2/en active Active
- 2019-01-30 CO CONC2019/0000932A patent/CO2019000932A2/es unknown
- 2019-02-07 IL IL264710A patent/IL264710B/en unknown
- 2019-02-21 MX MX2021006902A patent/MX2021006902A/es unknown
- 2019-02-26 CL CL2019000512A patent/CL2019000512A1/es unknown
-
2020
- 2020-08-24 US US17/001,572 patent/US20200385387A1/en not_active Abandoned
-
2021
- 2021-06-24 AU AU2021204303A patent/AU2021204303B2/en active Active
-
2022
- 2022-01-17 JP JP2022004832A patent/JP7214900B2/ja active Active
- 2022-06-30 AU AU2022204697A patent/AU2022204697A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201901633WA (en) | 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201804170RA (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
| SG11201908813QA (en) | Anti-sirp alpha antibodies | |
| SG11201908569QA (en) | Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201908604YA (en) | Fused imidazo-piperidine jak inhibitor compound | |
| SG11201805940QA (en) | Benzopyrazole compounds and analogues thereof | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201810594RA (en) | Nucleic acid molecules for reduction of papd5 or papd7 mrna for treating hepatitis b infection | |
| SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
| SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
| SG11201811470PA (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
| SG11201901457TA (en) | 2'-substituted-n6-substituted purine nucleotides for rna virus treatment | |
| SG11201809537VA (en) | Urea motif containing compounds and derivatives thereof as antibacterial drugs | |
| SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
| SG11201811363YA (en) | Anti-zika virus antibodies and methods of use | |
| SG11201807051VA (en) | Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors |